Palisade Bio, Inc. (Nasdaq: PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company developing next-generation prodrugs for patients living with inflammatory and fibrotic diseases, today announced that Health Canada has cleared the Company’s Clinical Trial Application (CTA) for ASCENTRA-UC, its global Phase 2 study evaluating PALI-2108 in patients with moderately to severely active ulcerative colitis (UC).

The clearance enables Palisade to advance clinical trial activities in Canada, expanding the study’s geographic reach and supporting planned enrollment. Together with prior regulatory clearance in the United States, this milestone advances the Company’s global site activation and enrollment strategy. Primary efficacy results from the study’s 12-week induction period are expected in the second half of 2027.